West Pharmaceutical Services, Inc. (NYSE:WST) Stock Has Average Price Target of $424.67

West Pharmaceutical Services, Inc. (NYSE:WST – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $424.67.

Several equities analysts have commented on WST shares. Weiss Ratings raised West Pharmaceutical Services from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, November 2nd. TD Cowen lifted their target price on West Pharmaceutical Services from $420.00 to $500.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Evercore reiterated an “outperform” rating and set a $425.00 target price on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Zacks Research lowered shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $475.00 price target on shares of West Pharmaceutical Services in a report on Monday, November 2nd.

Get Our Latest Stock Report on West Pharmaceutical Services

West Pharmaceutical Services Stock Up 0.2%

Shares of NYSE WST opened at $417.21 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.10. The company has a market cap of $29.06 billion, a P/E ratio of 46.82, a PEG ratio of 2.50 and a beta of 1.13. West Pharmaceutical Services has a 1 year low of $223.83 and a 1 year high of $438.27. The firm has a 50-day simple moving average of $381.87 and a two-hundred day simple moving average of $321.74.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last announced its earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.20 by $0.46. The business had revenue of $874.50 million during the quarter, compared to analyst estimates of $827.12 million. West Pharmaceutical Services had a return on equity of 21.78% and a net margin of 18.81%. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.96 earnings per share. Research analysts anticipate that West Pharmaceutical Services will post 9.45 earnings per share for the current year.

West Pharmaceutical Services Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 18th. Shareholders of record on Wednesday, November 11th will be given a $0.26 dividend. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Tuesday, November 10th. This represents a $1.04 annualized dividend and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio is presently 11.67%.

Insider Buying and Selling

In other news, VP Annette Favorite sold 8,135 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $340.81, for a total transaction of $2,772,489.35. Following the transaction, the vice president directly owned 16,845 shares of the company’s stock, valued at approximately $5,740,944.45. This trade represents a 32.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 15,659 shares of company stock valued at $5,443,749. 0.60% of the stock is owned by corporate insiders.

Institutional Trading of West Pharmaceutical Services

Several institutional investors and hedge funds have recently modified their holdings of WST. Addison Advisors LLC bought a new stake in West Pharmaceutical Services during the 2nd quarter valued at $28,000. Avalon Trust Co bought a new position in West Pharmaceutical Services during the 2nd quarter worth about $28,000. Virtus Advisers LLC bought a new position in West Pharmaceutical Services during the 3rd quarter worth about $37,000. Cornerstone Planning Group LLC increased its position in West Pharmaceutical Services by 90.9% during the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 50 shares during the period. Finally, Fulcrum Asset Management LLP increased its holdings in West Pharmaceutical Services by 259.4% during the third quarter. Fulcrum Asset Management LLP now owns 115 shares of the medical instruments supplier’s stock valued at $43,000 after buying an additional 83 shares during the period. Institutional investors own 93.90% of the company’s stock.

About West Pharmaceutical Services

(Get Free Report)

West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.

Featured Stories

Analyst Recommendations for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.